Literature DB >> 33616752

Investigating the anticancer properties of the two new platinum complexes with iso- and tert-pentylglycine by the DFT, molecular docking, and ADMET assessment and experimental confirmations.

Nadali Ramezani1, Mahboube Eslami Moghadam2, Mahdi Behzad1.   

Abstract

In this study, two new anticancer platinum complexes formulated as [Pt(bpy)(L)]NO3 were synthesized using the iso and tert-pentylglycine ligands, two structural isomer ligands, to investigate side branches effect on the complex-DNA interaction. According to the comparative results of the ADMET assessment, these compounds can be considered as the drug-like molecules and oral medication. Mechanism of tumor inhibition and DNA binding parameters indicated the higher ability of the tert-isomer and also, both complexes acted through the disruption of the base pairs and stacks of helicity by the endothermic process. Fluorescence spectroscopy showed that the quenching mechanism is static for both drugs with large binding constant and high binding affinity towards the DNA. Also, the amount of binding constant of the tert -isomer was about 14 times of another structural isomerous complex. CD spectra indicated the conversion of the B-DNA into A-DNA form via electrostatic interaction for positively charged complexes. The cytotoxic data showed that both compounds have antiproliferative effects against the MCF-7 cell line and the inhibitory effect of the iso-derivative was better than the tert-one. Docking studies showed that the desolvation energy and hydrogen bond are more effective between the other interactions. The torsional free energy for both complexes mainly provided the groove binding along with partially electrostatic and intercalate binding. According to the density-functional theory data and because of positive electron density on the surface of complexes and facilitating of the metal drug to DNA phosphate groups approaching, both complexes may be good candidates for the anticancer drugs. Two new anticancer Pt(II) complexes were synthesized with glycine derivatives. In vitro cytotoxicity effects were tested against the human breast cancer cell line of MCF-7. Moreover, the modes of DNA binding with synthesized compounds were investigated using ADME prediction, DFT, molecular docking and spectroscopic methods.

Entities:  

Keywords:  ADMET; Circular dichroism; DFT; DNA interaction; Fluorescence; Iso-pentylglycine; MCF-7; Molecular docking; Platinum anticancer complex; Tert-pentylglycine

Year:  2021        PMID: 33616752     DOI: 10.1007/s00775-021-01851-1

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  16 in total

1.  Anticancer activity of novel amino acid derivative of palladium complex with phendione ligand against of human colon cancer cell line.

Authors:  Hossein Farhangian; Mahboube Eslami Moghadam; Adeleh Divsalar; Arezo Rahiminezhad
Journal:  J Biol Inorg Chem       Date:  2017-08-04       Impact factor: 3.358

2.  Spectroscopic and theoretical investigation of oxali-palladium interactions with β-lactoglobulin.

Authors:  Behafarid Ghalandari; Adeleh Divsalar; Ali Akbar Saboury; Thomas Haertlé; Kazem Parivar; Roya Bazl; Mahbube Eslami-Moghadam; Massoud Amanlou
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2013-10-08       Impact factor: 4.098

3.  Synthesis of spherical Fe3O4 nanoparticles from the thermal decomposition of iron (III) nano-structure complex: DFT studies and evaluation of the biological activity.

Authors:  Nahid Zare; Abedien Zabardasti; Abdelnasser Mohammadi; Farideh Azarbani
Journal:  Bioorg Chem       Date:  2018-07-03       Impact factor: 5.275

4.  Binding properties of a new anti-tumor component (2,2'-bipyridin octylglycinato Pd(II) nitrate) with bovine beta-lactoglobulin-A and -B.

Authors:  A Divsalar; A A Saboury; H Mansoori-Torshizi; A A Moosavi-Movahedi
Journal:  J Biomol Struct Dyn       Date:  2007-10

5.  Synthesis, cytotoxicity assessment, and interaction and docking of novel palladium(II) complexes of imidazole derivatives with human serum albumin.

Authors:  Mahboube Eslami Moghadam; Adeleh Divsalar; Abdolghafar Abolhosseini Shahrnoy; Ali Akbar Saboury
Journal:  J Biomol Struct Dyn       Date:  2015-10-20

6.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

Review 7.  Conformational changes in DNA upon ligand binding monitored by circular dichroism.

Authors:  Yu-Ming Chang; Cammy K-M Chen; Ming-Hon Hou
Journal:  Int J Mol Sci       Date:  2012-03-12       Impact factor: 6.208

Review 8.  Metal complexes in cancer therapy - an update from drug design perspective.

Authors:  Umar Ndagi; Ndumiso Mhlongo; Mahmoud E Soliman
Journal:  Drug Des Devel Ther       Date:  2017-03-03       Impact factor: 4.162

9.  Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.

Authors:  Chong Zhao; Xin Chen; Dan Zang; Xiaoying Lan; Siyan Liao; Changshan Yang; Peiquan Zhang; Jinjie Wu; Xiaofen Li; Ningning Liu; Yuning Liao; Hongbiao Huang; Xianping Shi; Lili Jiang; Xiuhua Liu; Zhimin He; Xuejun Wang; Jinbao Liu
Journal:  Biochem Pharmacol       Date:  2016-07-02       Impact factor: 5.858

Review 10.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

View more
  3 in total

1.  Structural characterization and antileishmanial activity of newly synthesized organo-bismuth(V) carboxylates: experimental and molecular docking studies.

Authors:  Sohaila Andleeb; Muhammad Khawar Rauf; Syed Sikander Azam; Ihsan-Ul Haq; Muhammad Nawaz Tahir; Naila Zaman
Journal:  J Biol Inorg Chem       Date:  2022-01-04       Impact factor: 3.358

2.  Property evaluation of two anticancer candidate platinum complexes with N-isobutyl glycine ligand against human colon cancer.

Authors:  Zahra Hosseini Hashemi; Masoud Mirzaei; Mahboube Eslami Moghadam
Journal:  Biometals       Date:  2022-07-13       Impact factor: 3.378

3.  Synthesis and characterization of two new mixed-ligand Cu(II) complexes of a tridentate NN'O type Schiff base ligand and N-donor heterocyclic co-ligands: In vitro anticancer assay, DNA/human leukemia/COVID-19 molecular docking studies, and pharmacophore modeling.

Authors:  Liana Ghasemi; Mahdi Behzad; Ali Khaleghian; Alireza Abbasi; Anita Abedi
Journal:  Appl Organomet Chem       Date:  2022-02-24       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.